WO2008076868A3 - Methods and compositions related to modulation of receptor tyrosine kinase orphan receptor-1 (ror-1) - Google Patents

Methods and compositions related to modulation of receptor tyrosine kinase orphan receptor-1 (ror-1) Download PDF

Info

Publication number
WO2008076868A3
WO2008076868A3 PCT/US2007/087542 US2007087542W WO2008076868A3 WO 2008076868 A3 WO2008076868 A3 WO 2008076868A3 US 2007087542 W US2007087542 W US 2007087542W WO 2008076868 A3 WO2008076868 A3 WO 2008076868A3
Authority
WO
WIPO (PCT)
Prior art keywords
ror
methods
receptor
tyrosine kinase
modulation
Prior art date
Application number
PCT/US2007/087542
Other languages
French (fr)
Other versions
WO2008076868A2 (en
Inventor
Donald J Davidson
Catherine J Haskell
Original Assignee
Abbott Lab
Donald J Davidson
Catherine J Haskell
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Abbott Lab, Donald J Davidson, Catherine J Haskell filed Critical Abbott Lab
Publication of WO2008076868A2 publication Critical patent/WO2008076868A2/en
Publication of WO2008076868A3 publication Critical patent/WO2008076868A3/en

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/566—Immunoassay; Biospecific binding assay; Materials therefor using specific carrier or receptor proteins as ligand binding reagents where possible specific carrier or receptor proteins are classified with their target compounds
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/90—Enzymes; Proenzymes
    • G01N2333/91—Transferases (2.)
    • G01N2333/912—Transferases (2.) transferring phosphorus containing groups, e.g. kinases (2.7)
    • G01N2333/91205—Phosphotransferases in general
    • G01N2333/9121—Phosphotransferases in general with an alcohol group as acceptor (2.7.1), e.g. general tyrosine, serine or threonine kinases
    • G01N2333/91215—Phosphotransferases in general with an alcohol group as acceptor (2.7.1), e.g. general tyrosine, serine or threonine kinases with a definite EC number (2.7.1.-)
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/52—Predicting or monitoring the response to treatment, e.g. for selection of therapy based on assay results in personalised medicine; Prognosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Biomedical Technology (AREA)
  • Hematology (AREA)
  • Urology & Nephrology (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Biochemistry (AREA)
  • Physics & Mathematics (AREA)
  • Food Science & Technology (AREA)
  • Microbiology (AREA)
  • Analytical Chemistry (AREA)
  • Cell Biology (AREA)
  • Biotechnology (AREA)
  • General Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Organic Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biophysics (AREA)
  • Hospice & Palliative Care (AREA)
  • Oncology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)

Abstract

The present invention relates to the discovery of the role of tyrosine kinase orphan receptor-1 (ROR-1) and its interactions with glucose-regulated protein 78 (GRP78) and Wnt in processes such as angiogenesis and apoptosis. The invention provides diagnostic methods based on ROR-1 and GRP78, as well as methods of modulating ROR-1, antibodies specific for ROR-1, GRP78, and Wnt, and related screening methods.
PCT/US2007/087542 2006-12-18 2007-12-14 Methods and compositions related to modulation of receptor tyrosine kinase orphan receptor-1 (ror-1) WO2008076868A2 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US87548106P 2006-12-18 2006-12-18
US60/875,481 2006-12-18

Publications (2)

Publication Number Publication Date
WO2008076868A2 WO2008076868A2 (en) 2008-06-26
WO2008076868A3 true WO2008076868A3 (en) 2008-10-09

Family

ID=39345130

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2007/087542 WO2008076868A2 (en) 2006-12-18 2007-12-14 Methods and compositions related to modulation of receptor tyrosine kinase orphan receptor-1 (ror-1)

Country Status (1)

Country Link
WO (1) WO2008076868A2 (en)

Cited By (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8843187B2 (en) 2003-08-22 2014-09-23 Dexcom, Inc. Systems and methods for replacing signal artifacts in a glucose sensor data stream
US8915849B2 (en) 2003-08-01 2014-12-23 Dexcom, Inc. Transcutaneous analyte sensor
US9107623B2 (en) 2003-12-09 2015-08-18 Dexcom, Inc. Signal processing for continuous analyte sensor
US9320466B2 (en) 2009-07-02 2016-04-26 Dexcom, Inc. Analyte sensor
US9523695B2 (en) 2011-01-14 2016-12-20 The Regents Of The University Of California Therapeutic antibodies against ROR-1 protein and methods for use of same
US9538946B2 (en) 2003-11-19 2017-01-10 Dexcom, Inc. Integrated receiver for continuous analyte sensor
CN108103192B (en) * 2017-11-20 2021-08-13 广东医科大学 Cancer early stage screening kit based on detection of peripheral blood GRP78 gene promoter methylation

Families Citing this family (41)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8260393B2 (en) 2003-07-25 2012-09-04 Dexcom, Inc. Systems and methods for replacing signal data artifacts in a glucose sensor data stream
US9247901B2 (en) 2003-08-22 2016-02-02 Dexcom, Inc. Systems and methods for replacing signal artifacts in a glucose sensor data stream
US9282925B2 (en) 2002-02-12 2016-03-15 Dexcom, Inc. Systems and methods for replacing signal artifacts in a glucose sensor data stream
US7591801B2 (en) 2004-02-26 2009-09-22 Dexcom, Inc. Integrated delivery device for continuous glucose sensor
US20190357827A1 (en) 2003-08-01 2019-11-28 Dexcom, Inc. Analyte sensor
US8761856B2 (en) 2003-08-01 2014-06-24 Dexcom, Inc. System and methods for processing analyte sensor data
US20140121989A1 (en) 2003-08-22 2014-05-01 Dexcom, Inc. Systems and methods for processing analyte sensor data
US7920906B2 (en) 2005-03-10 2011-04-05 Dexcom, Inc. System and methods for processing analyte sensor data for sensor calibration
US9247900B2 (en) 2004-07-13 2016-02-02 Dexcom, Inc. Analyte sensor
US8423114B2 (en) 2006-10-04 2013-04-16 Dexcom, Inc. Dual electrode system for a continuous analyte sensor
US8364231B2 (en) 2006-10-04 2013-01-29 Dexcom, Inc. Analyte sensor
US8532730B2 (en) 2006-10-04 2013-09-10 Dexcom, Inc. Analyte sensor
US11633133B2 (en) 2003-12-05 2023-04-25 Dexcom, Inc. Dual electrode system for a continuous analyte sensor
US8808228B2 (en) 2004-02-26 2014-08-19 Dexcom, Inc. Integrated medicament delivery device for use with continuous analyte sensor
US8452368B2 (en) 2004-07-13 2013-05-28 Dexcom, Inc. Transcutaneous analyte sensor
US7654956B2 (en) 2004-07-13 2010-02-02 Dexcom, Inc. Transcutaneous analyte sensor
CA2688184A1 (en) 2007-06-08 2008-12-18 Dexcom, Inc. Integrated medicament delivery device for use with continuous analyte sensor
EP4159114B1 (en) 2007-10-09 2024-04-10 DexCom, Inc. Integrated insulin delivery system with continuous glucose sensor
WO2009105709A1 (en) 2008-02-21 2009-08-27 Dexcom, Inc. Systems and methods for processing, transmitting and displaying sensor data
US9149220B2 (en) 2011-04-15 2015-10-06 Dexcom, Inc. Advanced analyte sensor calibration and error detection
US9446194B2 (en) 2009-03-27 2016-09-20 Dexcom, Inc. Methods and systems for promoting glucose management
EP2424435B1 (en) 2009-04-30 2021-06-02 Dexcom, Inc. Performance reports associated with continuous sensor data from multiple analysis time periods
EP2513146B1 (en) 2009-12-18 2017-05-03 Kancera AB Antibodies against ror1 capable of inducing cell death of cll
GB2476293A (en) * 2009-12-18 2011-06-22 Biolnvent Internat Ab Therapeutic inhibition of ROR-1
US9242014B2 (en) 2010-06-15 2016-01-26 The Regents Of The University Of California Receptor tyrosine kinase-like orphan receptor 1 (ROR1) single chain Fv antibody fragment conjugates and methods of use thereof
EP3828205A1 (en) * 2010-10-01 2021-06-02 Oxford BioTherapeutics Ltd Anti-ror1 antibodies
GB201020995D0 (en) 2010-12-10 2011-01-26 Bioinvent Int Ab Biological materials and uses thereof
US9085772B2 (en) 2010-12-27 2015-07-21 National University Corporation Nagoya University Method for suppressing receptor tyrosine kinase-mediated pro-survival signaling in cancer cell
MY181648A (en) 2012-08-24 2020-12-30 Univ California Antibodies and vaccines for use in treating ror1 cancers and inhibiting metastasis
EP2789630A1 (en) 2013-04-09 2014-10-15 EngMab AG Bispecific antibodies against CD3e and ROR1
EP3204415B1 (en) 2014-10-09 2020-06-17 EngMab Sàrl Bispecific antibodies against cd3epsilon and ror1
JP5770908B1 (en) * 2014-10-24 2015-08-26 比奈子 山崎 Clothesline
WO2016187220A2 (en) 2015-05-18 2016-11-24 Five Prime Therapeutics, Inc. Anti-ror1 antibodies
EA201891066A1 (en) 2015-10-30 2018-10-31 ЭнБиИ-ТЕРАПЬЮТИКС АГ ANTIBODIES TO ROR1
WO2017127664A1 (en) 2016-01-20 2017-07-27 The Scripps Research Institute Ror1 antibody compositions and related methods
CA3029003A1 (en) 2016-06-27 2018-01-04 The Regents Of The University Of California Cancer treatment combinations
CA3030841A1 (en) 2016-07-14 2018-01-18 Fred Hutchinson Cancer Research Center Multiple bi-specific binding domain constructs with different epitope binding to treat cancer
SG11202000846WA (en) 2017-08-07 2020-02-27 Nbe Therapeutics Ag Anthracycline-based antibody drug conjugates having high in vivo tolerability
US11943876B2 (en) 2017-10-24 2024-03-26 Dexcom, Inc. Pre-connected analyte sensors
US11331022B2 (en) 2017-10-24 2022-05-17 Dexcom, Inc. Pre-connected analyte sensors
WO2019225777A1 (en) * 2018-05-23 2019-11-28 에이비엘바이오 주식회사 Anti-ror1 antibody and use thereof

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2004094641A2 (en) * 2003-04-16 2004-11-04 Wyeth A novel method of modulating bone-realted activity
WO2006039173A2 (en) * 2004-09-22 2006-04-13 Abbott Laboratories Uses of an endothelial cell receptor

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2004094641A2 (en) * 2003-04-16 2004-11-04 Wyeth A novel method of modulating bone-realted activity
WO2006039173A2 (en) * 2004-09-22 2006-04-13 Abbott Laboratories Uses of an endothelial cell receptor

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
CHEN LIGUANG ET AL: "Expression of ROR1 in chronic lymphocytic leukemia cells enhances cells survival by Wnt5a signaling", BLOOD, vol. 110, no. 11, Part 1, November 2007 (2007-11-01), & 49TH ANNUAL MEETING OF THE AMERICAN-SOCIETY-OF-HEMATOLOGY; ATLANTA, GA, USA; DECEMBER 08 -11, 2007, pages 107A, XP009100073, ISSN: 0006-4971 *
KATOH MASUKO ET AL: "Comparative genomics on ROR1 and ROR2 orthologs", ONCOLOGY REPORTS, NATIONAL HELLENIC RESEARCH FOUNDATION, ATHENS, GR, vol. 14, no. 5, 1 November 2005 (2005-11-01), pages 1381 - 1384, XP009100071, ISSN: 1021-335X *

Cited By (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8915849B2 (en) 2003-08-01 2014-12-23 Dexcom, Inc. Transcutaneous analyte sensor
US8843187B2 (en) 2003-08-22 2014-09-23 Dexcom, Inc. Systems and methods for replacing signal artifacts in a glucose sensor data stream
US9427183B2 (en) 2003-08-22 2016-08-30 Dexcom, Inc. Systems and methods for replacing signal artifacts in a glucose sensor data stream
US9538946B2 (en) 2003-11-19 2017-01-10 Dexcom, Inc. Integrated receiver for continuous analyte sensor
US9107623B2 (en) 2003-12-09 2015-08-18 Dexcom, Inc. Signal processing for continuous analyte sensor
US9498155B2 (en) 2003-12-09 2016-11-22 Dexcom, Inc. Signal processing for continuous analyte sensor
US9320466B2 (en) 2009-07-02 2016-04-26 Dexcom, Inc. Analyte sensor
US9523695B2 (en) 2011-01-14 2016-12-20 The Regents Of The University Of California Therapeutic antibodies against ROR-1 protein and methods for use of same
CN108103192B (en) * 2017-11-20 2021-08-13 广东医科大学 Cancer early stage screening kit based on detection of peripheral blood GRP78 gene promoter methylation

Also Published As

Publication number Publication date
WO2008076868A2 (en) 2008-06-26

Similar Documents

Publication Publication Date Title
WO2008076868A3 (en) Methods and compositions related to modulation of receptor tyrosine kinase orphan receptor-1 (ror-1)
WO2009052400A8 (en) Antibodies that bind to mammalian ngal and uses thereof
WO2006053771A3 (en) Agonists of bitter taste receptors and uses thereof
WO2010037041A3 (en) Frizzled-binding agents and uses thereof
MX2010007841A (en) Improved anti-trkb antibodies.
WO2011038301A3 (en) Screening methods
WO2010002862A3 (en) Fibroblast growth factor receptor 3 (fgfr3) binding proteins
WO2005118857A3 (en) Methods and agents for screening for compounds capable of modulating vegf expression
EA201001223A1 (en) STABILIZED PROTEIN COMPOSITIONS
WO2008060705A8 (en) Anti-dll4 antibodies and methods using same
MY156315A (en) Anti-vegf antibodies
WO2010031076A3 (en) Conversion of prenyl derivatives to isoprene
WO2008106200A3 (en) Human anti-ip-10 antibodies and uses thereof
WO2011069156A3 (en) Compositions and methods for enhancing odorant receptor activity
GEP20125398B (en) Human monoclonal antibodies to activin receptor-like kinase-1
WO2011123785A3 (en) Frizzled-binding agents and uses thereof
WO2007120766A3 (en) Erythropoietin receptor agonists
WO2006086150A3 (en) Phuman t2r receptors for acetaminophen, ranitidine, strychnine and denatonium and related assays for identifying human bitter taste modulators
WO2008020942A3 (en) R-spondin compositions and methods of use thereof
WO2008021250A3 (en) Compositions and methods for modulating apoptosis in cells over-expressing bcl-2 family member proteins
WO2007098198A3 (en) Modulation of bone formation
WO2009048769A3 (en) Vaccinia virus h3l and b5r specific monoclonal antibodies and methods of making and using same
WO2008030429A3 (en) Novel haplotype of human t2r receptor ht2r50 and its use in assays for identifying human bitter taste modulators
WO2007075899A8 (en) Dual agonist compounds and uses thereof
WO2008027855A3 (en) Compositions and methods for modulating mtor signaling

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 07855160

Country of ref document: EP

Kind code of ref document: A2

NENP Non-entry into the national phase

Ref country code: DE

122 Ep: pct application non-entry in european phase

Ref document number: 07855160

Country of ref document: EP

Kind code of ref document: A2